Subscribe

Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Slow but positive change? The evolution of section 3d
Asia
Slow but positive change? The evolution of section 3d
New definitions of efficacy are helping to clarify pharmaceutical patent challenges under the notorious Section 3d of the Indian Patents Act, says Rahul Vartak.   1 April 2013
Considerations for biopharma under a first-inventor-to-file regime
Americas
Considerations for biopharma under a first-inventor-to-file regime
The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system.   1 April 2013
Biotech threats in the SPC system
Biotechnology
Biotech threats in the SPC system
In its effort to tackle the threat of ‘evergreening’, the CJEU has caused some uncertainty about supplementary protection certificates, as Jaap Mannaerts explains.   1 April 2013
Americas
Post-grant patent challenges in Europe and the US: harmony at last?
Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.   1 April 2013
Europe
The European take on the Bolar provision: conclusions from Astellas v Polpharma
While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.   1 April 2013
Big Pharma
Twenty-one years of SPCs – a cause for celebration?
Gordon Wright reviews the key SPC cases as Europe’s SPC Regulation for medicinal products approaches its 21st birthday.   28 March 2013
Big Pharma
The likely role of the UPC in pharma patent litigation
The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.   28 March 2013
Big Pharma
Confidence in the face of counterfeits
When most people hear the word counterfeiting, they think of fashion, but as Bruce Longbottom of Eli Lilly and Company explains, drugs are a key target too.   28 March 2013
Americas
Waiting to inhale: MannKind's diabetes strategy
For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities.   28 March 2013
Americas
AstraZeneca settles Crestor patent dispute
UK pharmaceutical company AstraZeneca has reached a settlement with Actavis and Egis Pharmaceuticals that delays the release of generic versions of its cholesterol treatment Crestor.   27 March 2013